How I treat cytopenias after CAR T-cell therapy
Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
A review of romiplostim mechanism of action and clinical applicability
JB Bussel, G Soff, A Balduzzi, N Cooper… - Drug design …, 2021 - Taylor & Francis
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy,
autoimmune disease, bone marrow disorders, pathologic conditions associated with …
autoimmune disease, bone marrow disorders, pathologic conditions associated with …
Eltrombopag added to immunosuppression in severe aplastic anemia
R Peffault de Latour, A Kulasekararaj… - … England Journal of …, 2022 - Mass Medical Soc
Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …
[HTML][HTML] Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells
Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in
relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that …
relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that …
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
G Drillet, F Lhomme, S De Guibert, G Manson… - Blood …, 2023 - ashpublications.org
COI notes: GD received honoraria from Janssen. FL received honoraria from Gilead
Sciences, Kite, Roch, and Janssen. SDG received honoraria from Gilead Sciences, AbbVie …
Sciences, Kite, Roch, and Janssen. SDG received honoraria from Gilead Sciences, AbbVie …
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries
P Scheinberg - British Journal of Haematology, 2021 - Wiley Online Library
The progress in aplastic anaemia (AA) management is one of success. Once an obscure
entity resulting in death in most affected can now be successfully treated with either …
entity resulting in death in most affected can now be successfully treated with either …
Inflammation and myeloid malignancy: quenching the flame
RJ Stubbins, U Platzbecker… - Blood, The Journal of the …, 2022 - ashpublications.org
Chronic inflammation with aging (“inflammaging”) plays a prominent role in the
pathogenesis of myeloid malignancies. Aberrant inflammatory activity affects many different …
pathogenesis of myeloid malignancies. Aberrant inflammatory activity affects many different …
[HTML][HTML] The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag
DJ Kuter - Blood Reviews, 2022 - Elsevier
Thrombopoietin regulates platelet production through activation of the thrombopoietin
receptor (TPO-R). TPO-R agonists (TPO-RAs) are available to treat thrombocytopenia in …
receptor (TPO-R). TPO-R agonists (TPO-RAs) are available to treat thrombocytopenia in …
HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation
Anemia of inflammation, also known as anemia of chronic disease, is refractory to
erythropoietin (EPO) treatment, but the mechanisms underlying the EPO refractory state are …
erythropoietin (EPO) treatment, but the mechanisms underlying the EPO refractory state are …